Beyond the Cleanroom: The Human and Technological Edge in Aseptic Manufacturing

Wednesday, January 1, 2025

True expertise in aseptic manufacturing is more than knowledge - it is a commitment to adapting practices to keep pace with emerging technologies, diseases, and regulatory requirements.

The pharmaceutical industry continuously evolves as it keeps pace with emerging threats to public health, burgeoning technologies, and new regulations, which at times introduce complex challenges to aseptic manufacturing. Nevertheless, no molecule is impossible to manufacture aseptically, given the right combination of creativity, flexibility, and technological adoption. Aseptic operations are a critical component of pharmaceutical manufacturing that, especially in the case of injectable drugs, keeps the medicine patients need safe for use.

Aseptic Processes: The Foundation of Pharmaceutical Manufacturing

Aseptic manufacturing involves the removal of three types of contaminants: microbial contamination - the presence of microorganisms; endotoxins - toxic components from the outer membrane of Gram-negative bacteria that are released when they die; and particulates - solid particles or dust that may make their way into the products.1,2 These contaminants can compromise product sterility and patient safety, making their exclusion paramount, especially in the manufacturing of injectable drugs that bypass natural protective barriers like the skin and gastrointestinal tract and directly enter the bloodstream.3,4 Aseptic processes mitigate these risks using sterilization techniques such as filtration, autoclaving, dry heat depyrogenation, and Gamma irradiation in some cases, environmental controls like maintaining positive air pressure and HEPA filtration and monitoring systems that detect microbial contamination and particulate levels in real-time.5 By implementing aseptic measures, manufacturers can establish the high level of control needed to meet the most stringent quality and safety standards.

Designing Sterile Facilities

The first step in developing aseptic processes begins with the manufacturing facility. HVAC systems, cleanroom layouts classified by particulate levels, and the control of airflow are core design principles when building a sterile facility.6 HVAC systems ensure regulated temperature, humidity, and air quality and are equipped with HEPA filters to remove ≥99.97% of particles 0.3 microns or larger.7 Cleanroom layouts incorporate features like segregated zones, unidirectional personnel, and material flow, and optimized placement of equipment and air filtration systems to minimize contamination risk and promote workflow efficiency.8 Proper airflow patterns, such as laminar flow, minimize contamination by maintaining a uniform, directed air movement.6

Key Components of Facility Design

  • Air Pressure Differentials:  Positive pressure within cleanrooms prevents unfiltered air and particulates from entering critical zones.9
  • Material and Personnel Flow: Facilities implement strategic separation of material and personnel pathways to reduce cross-contamination risks. One-way movement of personnel, coupled with designated gowning areas.10
  • Surfaces and Structural Design: Smooth, non-porous surfaces and rounded corners prevent microbial accumulation and reduce contamination risks.11
  • Machine Layout and product flow should also be considered.

Environmental Considerations When Planning a Facility

Environmental factors like climate, proximity to industrial zones, and external ecosystems dictate the need for robust filtration and isolation measures and, therefore, significantly impact facility design. Advanced air quality assessments detect contaminants outside the building, including industrial pollutants, microbial spores, and particulates, to better guide site selection.6

  • Climate and Humidity Control: Facilities in humid regions must incorporate dehumidification systems to prevent microbial growth, while arid climates may require systems for dealing with particulate contamination.7
  • Seismic and Weather Considerations: Structural reinforcements may be necessary to prevent damage and keep operations running in areas prone to natural disasters like earthquakes or floods.10

Ensuring Compliance Through Facility Design

Facility design must adhere to regulatory standards such as ISO 14644, the US Food and Drug Administration’s (FDA) Aseptic Processing Guidelines, and EudraLex good manufacturing processes (GMP) guidelines for environmental monitoring, airflow system, and validation processes. Teams must routinely conduct compliance audits to safeguard product quality.11

The Human Component of Aseptic Manufacturing

People are both the cornerstone and greatest risk in aseptic manufacturing. While machines and facilities lay the groundwork for a sterile environment, it is the operators who ensure the manufacturing is carried out aseptically. Operators must be trained to pay attention to detail while handling materials, documenting procedures, and adhering to protocols. Even with extensive training, human error will be a persistent challenge. Simple documentation mistakes or assumptions about process verification affect even the most experienced personnel and can have significant consequences. For example, an operator might assume a process was verified by a colleague when it was not, causing a critical step to be missed.

Positive reinforcement of good aseptic behaviors and repetition of training principles can go a long way toward reducing errors, regardless of the operator’s level of experience. These management strategies are part of a broader effort to make sure the workforce understands their important role in maintaining sterility.

In addition to training, management should foster a culture of accountability where every action is double-checked any communicated. The highest-risk tasks should be automated where possible. Reducing reliance on manual intervention will improve consistency and reliability.

Teach Operators to Take Ownership

A sense of ownership among team members can significantly improve their performance. Encouraging operators to take pride in their work and emphasizing the impact of their contributions - such as safe, effective medications reaching patients - builds a motivated team. Morning team discussions, regular feedback, and celebrating successes reinforce the importance of their roles, creating a culture where operators understand their work’s broader significance and can improve their work’s consistency and quality.

The Value of Expertise

True expertise in aseptic manufacturing is not learned in the classroom but is built on the production floor, dealing with real-world challenges and finding creative solutions in rreal-time Operators who start as cleanroom technicians and advance to leadership roles accumulate invaluable experience that supports consistent quality and sterility. Expertise leads to better decision-making and problem-solving when unexpected challenges arise, as experienced personnel can draw upon their knowledge of aseptic behavior, cleanroom dynamics, and regulatory requirements.

This is a very important hands-on experience, especially when manufacturing injectables, as minor deviations lead to serious consequences, such as compromising sterility or patient safety.

Expertise in this context goes beyond technical precision to encompass a deep understanding of microbial risks unique to injectable formulations, making certain that proactive measures against contamination are taken at every stage. Expertise bolsters the capability of production teams and delivers an understanding of the “why” of every step taken. This depth of understanding enables operators to identify potential issues proactively, adapt more quickly to the manufacture of new, more challenging molecules, and maintain the highest standards of product quality and safety.

Advancements in Technology

Reducing Human Error with Automation and AI

In recent years, robotic filling systems have taken over much of production by automating repetitive and delicate tasks, significantly reducing human-induced contamination risks. Robotic systems are used for several tasks, including sealing, vial filling, and labeling, while maintaining strict environmental controls and increasing sterility and consistency.12 They are also the only way to fill consistently without losing product in some situations, such as filling when there is not much product or when outputting very small volumes.

Filling very small doses is also very challenging without losing volume. Robotic systems are the only way to do that consistently and accurately without losing product.

In the coming years, AI will become more commonplace, working alongside robotics in aseptic manufacturing. While robotic systems perform tasks like material handling, equipment setup, and process monitoring, AI algorithms analyze sensor data to identify trends, predict failures, optimize workflows, and improve decision-making processes during production.13 Together, robotics and AI could lead to fully automated aseptic manufacturing facilities that achieve new levels of operational efficiency.

Single-Use Technologies

Single-use systems are essential in modern aseptic manufacturing. These are pre-sterilized systems that use disposable components like tubing, filters, and containers that eliminate the need for complex cleaning and sterilization processes. Single-use systems promote aseptic operational efficiency by minimizing cross-contamination risks and reducing downtime between production cycles. These systems have shown nearly 100% contamination prevention during high-risk aseptic processes by eliminating cleaning validation challenges and reducing human intervention.14 Likewise, they minimize the introduction of particulate matter, a common issue in traditional systems, making them particularly useful in the manufacture of injectables.15

Single-use systems help meet the increasing demand for scalable manufacturing solutions due to their ability to seamlessly transition between products and batches without needing to be cleaned.12 There is an environmental price to pay for this convenience however, by their nature, they are not reusable and must all be sent to landfill.

Real-Time Monitoring

Manufacturing has been streamlined without sacrificing product reliability and safety by shifting from retrospective quality checks to proactive monitoring.

Real-time monitoring systems constantly survey for critical environmental parameters, particulate levels, air quality, and microbial presence during aseptic manufacturing. These monitoring systems can detect deviations in real time and provide an opportunity for corrective actions to be made before contamination occurs.16

Dealing with Complex Challenges

Unique or difficult molecules can present significant challenges, but with the right expertise and creative problem-solving, any molecule or formulation can be manufactured aseptically. A mindset that views every challenge as an opportunity for innovation goes a long way when addressing a new molecule’s specific demands. Temperature sensitivity, susceptibility to contamination, Filter selection, product contact materials, and unique solubility properties are all considerations that require creativity, flexibility, and, most importantly, technical expertise to process from formulation to final fill.

For example, temperature adjustments can be used to stabilize sensitive molecules, and controlled agitation can promote homogeneity in viscous solutions without introducing particulates.17 Similarly, custom filtration setups effectively address challenges related to molecular size or solubility by using filters to remove particulates while maintaining sterility.18 There are many solutions to problems that would only occur to an expert with a deep understanding of aseptic processing who can identify the most effective approaches, anticipate potential issues, and implement innovative solutions to meet these demands.

Navigating the Regulatory Landscape

Aseptic manufacturing requires a delicate balance of innovation and regulatory compliance. The increased complexity of pharmaceutical formulations frequently pushes the boundaries of current guidelines, and proactive engagement with regulatory bodies such as the (FDA) and the European Medicines Agency (EMA) is important. Key regulatory frameworks, such as the FDA’s Current Good Manufacturing Practices (CGMP) and ISO 13485 related to medical devices, have imposed strict process validations, including sterilization methods, equipment design, and cleanroom operations. Successful aseptic manufacturing demands a continuous commitment to aligning cutting-edge innovations like AI-managed workflow systems with rigorous regulatory standards to manufacture products safely.

Validation and Quality Management

Validation processes exist to check that aseptic manufacturing systems consistently deliver safe, high-quality products. Expertise is critical for thoroughly qualifying equipment, processes, and personnel and adapting to changes in products and evolving regulatory expectations (Singh & Mehta, 2020).19 A robust Quality Risk Management (QRM) approach, guided by skilled professionals, strengthens compliance by proactively identifying and mitigating risks at every stage, ensuring sterility from material sourcing to final product release.

Enabling Global Distribution

The global distribution of aseptic products depends on meeting international quality standards, for which technical expertise and innovative solutions are needed simultaneously. Skilled manufacturers have to meet not only a variety of regulatory requirements but also implement forward-thinking approaches to keep their products safe and effective under changing global conditions.

Manufacturers can couple strict compliance with forward-looking innovation to ensure that, in the event of changing regulations, aseptic products are safe, effective, and available worldwide.

Positioning Aseptic Manufacturing for Success

The aseptic manufacturing of the future will thrive on the nexus between expertise and adaptability. As new challenges arise, from evolving diseases to new regulatory guidelines, the industry must ground itself in foundational knowledge while embracing forward-thinking innovation. Expertise is never static; it has to be nurtured with continuous learning and a hunger for exploring new aseptic technologies.

In conjunction with expertise and adaptability, aseptic manufacturing professionals are best positioned to tackle complex formulations, address unforeseen challenges, and ensure that every dose meets the highest standards of safety and efficacy.

Author Details 

Samuel Chia- Senior Director of Operations MS&T, Pharmaceutics International, Inc. (Pii)

Sam Chia is the Senior Director of Operations MS&T at Pharmaceutics International, Inc. (Pii), with over 26 years of experience in aseptic manufacturing and sterile processing. He has held several leadership positions, including Director of Aseptic Operations and Plant Manager at ImprimisRx, a division of Harrow Pharmaceuticals. His career spans roles in production and operations optimization. Sam is fluent in both English and French, which complements his extensive international experience in pharmaceutical manufacturing and operational management across the United States and beyond.

Sam has been involved in startup operations in several big pharma companies, including Ben Venue Laboratories, a division of Boehringer Ingelheim, and Cangene Biopharma, formerly known as Chesapeake Biological Laboratories, now Bora Pharmaceuticals. Sam is an Associate Member of the Royal Society of Chemistry in England and holds a BS degree in chemistry with a biochemistry minor.

References

  1. Tidswell EC. A nontrivial analysis of patient safety risk from parenteral drug- and medical device-borne endotoxin. Drugs in R&D. 2023;23(1):65-76. doi:10.1007/s40268-023- 00412-y
  2. Langille SE. Particulate matter in injectable drug products. PDA Journal of Pharmaceutical Science and Technology. 2013;67(3):186-200. doi:10.5731/pdajpst.2013.00922
  3. Phogat J. Sterile formulations. In: A Textbook of Pharmaceutics for I Year Diploma in Pharmacy. ThinkPlus Pharma Publications; 2024:598-643. doi:10.69613/vxhfeh32
  4. Mehta RC, Murty R. Laboratory techniques in aseptic manufacturing. In: Aseptic Pharmaceutical Manufacturing II. CRC Press; 1995. doi:10.1201/9781003070467-6
  5. Del Rio-Alvarez L, Salazar-Sanchez N. Technological challenges in sterile product manufacturing: Is the pharmaceutical industry trained? DYNA. 2022;97(2):135-139. doi:10.6036/10288
  6. Bottani E, Rizzo R, Vignali G. Numerical simulation of turbulent air flows in aseptic clean rooms. I-Tech Education and Publishing. 2008. doi:10.5772/5962
  7. Moore BD. Air handling systems for cleanroom control. In: Process Engineering Applications. 2018:37-88. doi:10.1201/9780203738320-3
  8. International Organization for Standardization. ISO 14644-1:2015 Cleanrooms and Associated Controlled Environments—Part 1: Classification of Air Cleanliness by Particle Concentration. ISO; 2015.
  9. Iwamura T, Nagano K, Nogami T, et al. Confirmation of the sterilization effect using a high concentration of ozone gas for the bio-clean room. Biocontrol Science. 2013;18(1):9-20. doi:10.4265/bio.18.9
  10. Park D-I, Chung K-S, Kim Y-I, Kim S-M. A study on the development of oxygen cluster ion generator for sterilization of bio clean room (BCR). Korean Journal of Air-Conditioning and Refrigeration Engineering. 2013;25(1):7-13. doi:10.6110/KJACR.2013.25.1.007
  11. Bhattacharya A, Tak MS, Shoai-Naini S, Betz F, Mousavi E. A systematic literature review of cleanroom ventilation and air distribution systems. Aerosol and Air Quality Research. 2023;23:220407. doi:10.4209/aaqr.220407
  12. Pathak S, Deepika NM, Rajalakshmi B, et al. Enhancing robotic automation in industries using industrial informatics. Presented at: 2024 IEEE 13th International Conference on Communication Systems and Network Technologies (CSNT); 2024; Jabalpur, India:484-490. doi:10.1109/CSNT60213.2024.10546155
  13. Lincy SSB. Artificial intelligence (AI) driven industrial automation. In: Industry Automation: The Technologies, Platforms, and Use Cases. River Publishers; 2024:85-100. doi:10.1201/9781003516668-4
  14. Batt N, Biel S, Le Raye C, Rutigliani N. Single-use systems in aseptic processing: Sterility risk mitigation using a point of use integrity test. Chemie Ingenieur Technik. 2022;94(12):1985- 1994. doi:10.1002/cite.202200113
  15. Wormuth K, Gaston F, Gauthier M, Cantin V, Montenay N. Best practices to quantify and identify particulate matter on the interior surfaces of single-use systems. PDA Journal of Pharmaceutical Science and Technology. 2023;77(1):90-99.
  16. Weber J, Hauschild JE, IJzerman-Boon PC, et al. Continuous microbiological environmental monitoring for process understanding and reduced interventions in aseptic manufacturing. PDA Journal of Pharmaceutical Science and Technology. 2019;73(2):121-134.
  17. Bódis A, Benkóczy Z, Gondár E, Illés J, Neszmélyi E. Filtration of solutions with high viscosity: From laboratory experiments to production. Acta Pharmaceutica Hungarica. 1998;68(2):127-132.
  18. Belgaid A, Benaji B, Aadil N, Moussamih S, Khayati Y, Benchekroune T. Sterilization of the aseptic drug by sterile filtration: Microbiology validation by a microbiology challenge test. Journal of Chemical and Pharmaceutical Research. 2014;6(12):760-770.
  19. Singh S, Mehta D. Sterilization of pharmaceutical dosage forms. In: Drug Delivery Aspects: Expectations and Realities of Multifunctional Drug Delivery Systems. Elsevier; 2020:169- 190. doi:10.1016/B978-0-12-821222-6.00008-7

Publication Details

This article appeared in American Pharmaceutical Review:
Vol. 28, No. 1
Jan/Feb 2025
Pages: 16-19
 

Subscribe to our e-newsletters.
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!

  • <<
  • >>

Join the Discussion